Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE versus WESTADONE.
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a full mu-opioid receptor agonist, exerting analgesic and antitussive effects by binding to opioid receptors in the CNS and cough center. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1 tablet (hydrocodone 5 mg/chlorpheniramine 4 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Hydrocodone: 3.8-8.5 hours (mean 5.3 hours); context: immediate-release, dosing intervals typically 4-6 hours. Chlorpheniramine: terminal half-life 12-43 hours (mean 21 hours); context: longer half-life supports twice-daily dosing, but effects may not correlate linearly.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Hydrocodone: primarily renal excretion as unchanged drug and conjugated metabolites (approx. 26% unchanged); minor biliary/fecal elimination. Chlorpheniramine: renal excretion of metabolites and unchanged drug (approx. 30% unchanged), with some fecal elimination.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist